文献速递乳腺癌妇科肿瘤

癌症疫苗在乳腺癌与卵巢癌中的疗效:20年系统综述与荟萃分析

Efficacy of cancer vaccines in selected gynaecological breast and ovarian cancers: A 20-year systematic review and meta-analysis.
PubMed 文献 · Eur J Cancer · 2020-11-19

该研究系统检索2000年至2020年PubMed数据库,纳入67项研究(乳腺癌46项1698例,卵巢癌32项426例),评估治疗性癌症疫苗的疗效。乳腺癌汇总客观缓解率为9%(95%CI[5%,13%]),卵巢癌为4%(95%CI[1%,7%]),但中位生存期较长且毒性多为中度。

要点

  • 乳腺癌疫苗汇总ORR为9%(95%CI[5%,13%]),卵巢癌为4%(95%CI[1%,7%])。
  • 乳腺癌中位PFS为2.6个月,卵巢癌为13.0个月,中位OS分别为24.8个月和39.0个月。
  • 疫苗类型或治疗方案间未检测到统计学显著差异,毒性几乎均为中度。

核心结论

  • 尽管客观缓解率有限,过去20年治疗性疫苗在乳腺癌和卵巢癌中显示出相对较长的生存期和低毒性。

研究设计与样本

  • 系统综述与荟萃分析,检索PubMed数据库2000年1月1日至2020年2月4日,最终纳入67项研究(乳腺癌46项1698例,卵巢癌32项426例,其中11项同时涉及两种癌症)。

主要发现

  • 乳腺癌主要分析(21项研究428例)汇总ORR为9%(95%CI[5%,13%])。
  • 卵巢癌主要分析(12项研究182例)汇总ORR为4%(95%CI[1%,7%])。
  • 乳腺癌中位PFS为2.6个月(95%CI[1.9,2.9]),卵巢癌为13.0个月(95%CI[8.5,16.3])。
  • 乳腺癌中位OS为24.8个月(95%CI[15.0,46.0]),卵巢癌为39.0个月(95%CI[31.0,49.0])。
  • 按疫苗类型或治疗方案分组的亚组分析未检测到统计学显著差异,敏感性分析结果相似。

临床怎么用

  • 治疗性癌症疫苗在乳腺癌和卵巢癌中ORR有限但生存期较长且毒性低,可作为探索性治疗选择之一。

局限性

  • 需更好理解疫苗作用机制以进一步提高疗效。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Therapeutic cancer vaccination is an area of interest, even though promising efficacy has not been demonstrated so far. DESIGN: A systematic review and meta-analysis was conducted to evaluate vaccines' efficacy on breast cancer (BC) and ovarian cancer (OC) patients. Our search was based on the PubMed electronic database, from 1st January 2000 to 4th February 2020. OBJECTIVE: response rate (ORR) was the primary end-point of interest, while progression-free survival (PFS), overall survival (OS) and toxicity were secondary end-points. Analysis was performed separately for BC and OC patients. Pooled ORRs were estimated by fixed or random effects models, depending on the detected degree of heterogeneity, for all studies with more than five patients. Subgroup analyses by vaccine type and treatment schema as well as sensitivity analyses, were implemented. RESULTS: Among 315 articles initially identified, 67 were eligible for our meta-analysis (BC: 46, 1698 patients; OC: 32, 426 patients; where both BC/OC in 11). Dendritic-cell and peptide vaccines were found in more studies, 6/10 BC and 10/13 OC studies, respectively. In our primary BC analysis (21 studies; 428 patients), the pooled ORR estimate was 9% (95%CI[5%,13%]). The primary OC analysis (12 studies; 182 patients), yielded pooled ORR estimate of 4% (95%CI[1%,7%]). Similar were the results derived in sensitivity analyses. No statistically significant differences were detected by vaccine type or treatment schema. Median PFS was 2.6 months (95% confidence interval (CI)[1.9,2.9]) and 13.0 months (95%CI[8.5,16.3]) for BC and OC respectively, while corresponding median OS was 24.8 months (95%CI[15.0,46.0]) and 39.0 months (95%CI[31.0,49.0]). In almost all cases, the observed toxicity was only moderate. CONCLUSION: Despite their modest results in terms of ORR, therapeutic vaccines in the last 20 years display relatively long survival rates and low toxicity. Since a plethora of different approaches have been tested, a better understanding of the underlying mechanisms is needed in order to further improve vaccine efficacy.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Dafni U, Martín-Lluesma S, Balint K, et al. Efficacy of cancer vaccines in selected gynaecological breast and ovarian cancers: A 20-year systematic review and meta-analysis. Eur J Cancer. 2020. PMID: 33221598. doi:10.1016/j.ejca.2020.10.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。